Close
Digital Health & Ai Innovation summit 2026
APE 2026

Eko Launches SENSORA Cardiac Disease Detection Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Konica Minolta and deepc AI Partnership...

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed...

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand...

Novartis, which is a world-leading innovative medicines company, has...

Eko announced the launch of the SENSORA™ Cardiac Disease Detection Platform. SENSORA™ currently features AI which objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.

SENSORA™ is a cardiovascular disease detection platform combining the latest advancements in applied machine learning with one of the most ubiquitous medical devices in the world: the stethoscope. By capturing and analysing heart sounds and electrical signals with its digital stethoscopes.

The FDA-cleared SENSORA™ structural murmur detection helps health systems more accurately and consistently identify valvular heart disease (VHD) in patients during a routine visit with the primary care physician. VHD is a life-threatening condition diagnosed in more than 8 million Americans. VHD, when left undetected and untreated, can lead to heart failure, stroke, blood clots, and death. Older adults have a 1 in 10 chance of developing clinically significant VHD. However, more than half (57%) of clinically significant valvular heart disease goes undetected in this population. A primary care physician using SENSORA™ for structural murmur detection more than doubles likelihood of detecting significant VHD.

 

Latest stories

Related stories

Konica Minolta and deepc AI Partnership Expands Exa Platform

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed Go Smart MDI System

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand Therapy Facility

Novartis, which is a world-leading innovative medicines company, has...

Tempus-NYU Langone Collaboration Advances Precision Oncology

Tempus and NYU Langone Health have signed a multi-year...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »